Cystatin C at AACC 2020

Meet us at #2020AACC Virtual Exhibit Hall 

For its fourth consecutive year, Gentian Diagnostics will be participating in the AACC Annual Scientific Meeting & Clinical Lab Expo. This year’s all-virtual event promises to deliver the same breadth of world-class scientific content that attendees of prior AACC meetings would expect, albeit with greater accessibility and flexibility.

We invite you to use promo code 26138E for a free virtual Clinical Lab Expo pass. Please note that you will need to be registered with the AACC (its free) to use the promo code.

Cystatin C - Superior Kidney Marker¹

More than 4000 journal articles have been published on the clinical relevance of cystatin C since it was discovered as a marker of GFR in 1979 by Dr. Anders Grubb. The rising cost pressures faced by health systems has pushed cystatin C into the forefront of biomarkers that could reduce healthcare costs.

In light of this Gentian will be promoting its cystatin C assay during the 2020 AACC Scientific Meeting & Clinical Lab Expo. 25 years after the first automated assay for cystatin C was developed, Gentian emphasises the unique prognostic and diagnostic value of cystatin C as a marker that:

• Is independent of muscle mass^2-8
• Estimates GFR without race-adjustment⁹
• Correlates well with GFR within the “creatinine blind area”¹⁰
• Identifies chronic kidney disease (CKD) earlier than creatinine-based eGFR¹¹
• Ensures safety and efficacy of medications with a narrow therapeutic index^9,12

Visit us at our virtual booth #2020AACC

The virtual exhibit hall is open 24/7 from December 13^th, 2020 to January 18^th, 2021. You’ll be able to meet and chat live with the exhibitors during December 14^th-17^th 10 AM to 2 PM U.S. Central Time. Visit us during these opening hours or book a meeting in advance through marketing@gentian.com. 

Gentian Cystatin C Immunoassay 

• Particle-Enhanced Turbidimetric Immunoassay
• With avian antibodies for reduced interference 
• Can be applied on most automated platforms
• ERM-DA471/IFCC standardised
• FDA510 (k) cleared and CE-marked

Contact us now for more information

References: 

1. Dharnidharka VR et al. Am. J. Kidney Dis. 2002;40:221–226.
2. KDIGO Guidelines 2012 published in Kidney International Supplements Vol3 Issue 1, Jan 2013.
3. NCIC Clinical guideline (CG182) updated jan 2015 section 2.1 https://www.nice.org.uk/guidance/cg182/chapter/2-Implementation-getting-started.
4. Tangri N et al. Kidney Int 2011;79:471-7.
5. Grubb A et al. eJIFCC 2017 Vol 28 NO4 pp 268-276.
6. Bjork J et al. Pediatr Nephrol. 2019;34:1087–1098.
7. Lesly A et al. N Engl J Med 2012;367:20–29.
8. Schaeffner ES et al. Ann Intern Med 2012;157:471–481.
9. Ebert N et al. Curr Opin Nephrol Hypertens. 2020;29(6):591-598.
10. Lindström V. Low molecular mass proteins as markers for renal function and dialysis efficiency. Doctoral Dissertation, Lund University, 2013.
11. Murty MS et al. Indian J Nephrol. 2013;23(3):180-183.
12. Frazee E et al. Am J Kidney Dis. 2017;69(5):658-666.